We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSHP Director/PDMR Shareholding August 9, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transaction by person discharging managerial responsibilities and person closely associated with them Details of the person discharging managerial responsibilities 1. ("PDMR") / person closely associated them ("PCA") a) Name Kim Stratton / Peter Stratton 2. Reason for the notification Head of International Commercial (PDMR) / PCA of Kim a) Position / status Stratton Initial notification / b) amendment Initial notification Details of the issuer, emission allowance participant, 3. auction platform, auctioneer or auction monitor a) Name Shire plc b) LEI 54930005LQRLI2UXRQ59 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4. where transactions have been conducted Description of the financial instrument, Shire plc Ordinary Shares of 5 pence each ("Ordinary a) type of instrument Shares") Identification code ISIN: JE00B2QKY057 Transfer of Ordinary Shares held by Kim Stratton to a joint account held by Kim Stratton and Peter Stratton Nature of the and the pledge of such Ordinary Shares as security b) transaction for a loan. c) Price(s) and volume(s) Price(s) Volume(s) N/A 5,943 d) Aggregated information N/A (single transaction) - Aggregated volume - Price e) Date of the transaction August 8, 2017 f) Place of the Outside a trading venue transaction Oliver Strawbridge Senior Assistant Company Secretary For further information please contact: Investor Relations Ian Karp ikarp@shire.com +1 781 482 9018 Robert Coates rcoates@shire.com +44 1256 894874 Media Lisa Adler lisa.adler@shire.com +1 617 588 8607 Debbi Ford debbi.ford@shire.com +1 617 949 9083 NOTES TO EDITORS About Shire Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology. Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest. www.shire.com This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Shire plc via Globenewswire
(END) Dow Jones Newswires
August 09, 2017 09:30 ET (13:30 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions